High-dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma

Recent Results in Cancer Research

Volumn 183, Issue , 2011, Pages 207-238

  Haas, Rainer ^a   Bruns, Ingmar ^a   Kobbe, Guido ^a   Fenk, Roland ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CD34 ANTIGEN; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; INTERFERON; INTERLEUKIN 4; L SELECTIN; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 4;

AUTOGRAFT; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HIGH DOSE THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; LONG TERM CARE; LOW DRUG DOSE; LUNG TOXICITY; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PYREXIA IDIOPATHICA; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; T CELL DEPLETION; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FILGRASTIM; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 79955599139     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-85772-3_10     Document Type: Review

References (174)

1. Abdalla AO, Hansson L, Eriksson I, Nasman-Glaser B, Mellstedt H, Osterborg A (2007) Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients. Eur J Haematol 79:371-381 (Pubitemid 47556498)
2. Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB, Omri HE, Elloumi M, Belaaj H, Jeddi R, Aissaoui L, Ksouri H, Hassen AB, Msadek F, Saad A, Hsairi M, Boukef K, Amouri A, Louzir H, Dellagi K, Abdeladhim AB (2008) Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111:1805-1810 (Pubitemid 351451485)
3. + cells selected by immunomagnetic procedures in patients with multiple myeloma. Bone Marrow Transplant 22:957-963
4. Abraham R, Chen C, Tsang R, Simpson D, Murray C, Davidson M, Meharchand J, Sutton DM, Crump RM, Keating A, Stewart AK (1999) Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma. Bone Marrow Transplant 24:1291-1297 (Pubitemid 30052784)
5. + progenitors to peripheral blood. J Exp Med 185:111-120
6. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ Jr, Wilson HE (1969) Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 208:1680-1685
7. Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S (2004) Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 100:2607-2612 (Pubitemid 38715766)
8. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97 (Pubitemid 26240110)
9. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502 (Pubitemid 38010075)
10. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, Agha IY, Bourhis JH, Garderet L, Pegourie B, Dumontet C, Renaud M, Voillat L, Berthou C, Marit G, Monconduit M, Caillot D, Grobois B, Avet-Loiseau H, Moreau P, Facon T (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289-3294
11. Bahlis NJ, Mansoor A, Lategan JC, Valentine K, Thaell T, Blahey W, Savoie ML, Blaikie K, Kmet L, Roland B, Stewart DA (2006) Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14) in multiple myeloma: MM016 trial. Blood 108(11):3557
12. Bakkus MH, Bouko Y, Samson D, Apperley JF, Thielemans K, Van Camp B, Benner A, Goldschmidt H, Moos M, Cremer FW (2004) Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol 126:665-674 (Pubitemid 39221301)
13. Barbui AM, Galli M, Dotti G, Belli N, Borleri G, Gritti G, Bellavita P, Viero P, Comotti B, Barbui T, Rambaldi A (2002) Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol 116:202-210 (Pubitemid 34122082)
14. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789-793 (Pubitemid 27121271)
15. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65 (Pubitemid 29019388)
16. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC (2006a) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24:929-936 (Pubitemid 46638847)
17. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J (2006b) Thalidomide and hematopoietic- cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030 (Pubitemid 43357806)
18. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J (2008) Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112:3115-3121
19. Bellucci R, De Propris MS, Buccisano F, Lisci A, Leone G, Tabilio A, de Fabritiis P (1999) Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bone Marrow Transplant 23:1-8 (Pubitemid 29050171)
20. Bensinger W (2008) Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 26:480-492
21. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, Gooley T, Lynch M, Higano T, Klarnet J (1994) Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhGCSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87:825-831 (Pubitemid 24264657)
22. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD (1995) Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85:1655-1658
23. Bird JM, Bloxham D, Samson D, Marcus RE, Russell NH, Kelsey SM, Newland AC, Apperley JF (1994) Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol 88:110-116 (Pubitemid 24293861)
24. Bjorkstrand B (2001) European group for blood and marrow transplantation registry studies in multiple myeloma. Semin Hematol 38:219-225
25. Bjorkstrand B, Gahrton G (2007) High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future. Semin Hematol 44:227-233 (Pubitemid 47599548)
26. Blade J, Rosinol L, Sureda A, Ribera JM, Diaz- Mediavilla J, Garcia-Larana J, Mateos MV, Palomera L, Fernandez-Calvo J, Marti JM, Giraldo P, Carbonell F, Callis M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San MJ (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: longterm results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106:3755-3759 (Pubitemid 41739009)
27. Bleul CC, Farzan M, Choe H, Parolin C, Clark- Lewis I, Sodroski J, Springer TA (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382:829-833 (Pubitemid 26299570)
28. Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N (1958) Clinical experiences with sarcolysin in neoplastic diseases. Ann NY Acad Sci 68:1128-1132
29. Bogen B, Ruffini PA, Corthay A, Fredriksen AB, Froyland M, Lundin K, Rosjo E, Thompson K, Massaia M (2006) Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica 91:941-948 (Pubitemid 44023148)
30. + cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica 92:1083-1090
31. Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, Neumann F, Fischer J, Scheid C, Hubel K, Haas R, Kobbe G (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 46:180-185 (Pubitemid 43381751)
32. Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S, Singh R, Fenk R, Rosskopf M, Pechtel S, von Haeseler A, Wernet P, Tenen DG, Haas R, Kronenwett R (2008) Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 93:347-355 (Pubitemid 351398635)
33. Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion 1. Blood 107:159-166 (Pubitemid 43053538)
34. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, De Vivo A, Testoni N, Nicci C, Terragna C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M (2005) Superiority of thalidomide and dexamethasone over vincristine- doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35-39 (Pubitemid 40967171)
35. Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier LL, Pardoll DM, Housseau F (2006) Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 12:207-213 (Pubitemid 43214747)
36. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883 (Pubitemid 36532313)
37. Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A (1995) High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85:1596-1602
38. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, Van Lint MT, Bacigalupo A, Santoro A, Musso M, Majolino I, Boccadoro M, Pileri A (1999) Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 17:208-215 (Pubitemid 29022395)
39. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G (2003) Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 102:1927-1929 (Pubitemid 37022595)
40. + cell fractions of leukapheresis products do not contain malignant cells. Leukemia 11(Suppl 5):S41-S46
41. Cremer FW, Kiel K, Wallmeier M, Haas R, Goldschmidt H, Moos M (1998) Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Exp Hematol 26:969-975 (Pubitemid 28405462)
42. Cunningham D, Paz-Ares L, Gore ME, Malpas J, Hickish T, Nicolson M, Meldrum M, Viner C, Milan S, Selby PJ (1994) High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol 12:764-768 (Pubitemid 24110916)
43. Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di BC, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM (2007) Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idio-type (VDJ)-derived class I-restricted peptides. Br J Haematol 139:415-424 (Pubitemid 47512192)
44. + hematopoietic progenitor cells. Blood 89:3522-3528
45. + cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 13:1922-1932
46. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San MJ, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123-2132 (Pubitemid 350146107)
47. Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Loffler H, Muller-Ruchholtz W, Schmitz N (1994) G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 87:609-613 (Pubitemid 24230031)
48. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370:1209-1218 (Pubitemid 47516593)
49. Fenk R, Haas R, Kronenwett R (2004a) Molecular monitoring of minimal residual disease in patients with multiple myeloma. Hematology 9:17-33 (Pubitemid 38256008)
50. Fenk R, Ak M, Kobbe G, Steidl U, Arnold C, Korthals M, Hunerliturkoglu A, Rohr UP, Kliszewski S, Bernhardt A, Haas R, Kronenwett R (2004b) Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Haematologica 89:557-566 (Pubitemid 38691243)
51. Fenk R, Schneider P, Kropff M, Huenerlituerkoglu AN, Steidl U, Aul C, Hildebrandt B, Haas R, Heyll A, Kobbe G (2005a) High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol 130:588-594 (Pubitemid 43899763)
52. Fenk R, Graef T, Bruns I, Ruf L, Fabian Z, Steidl U, Huenerlituerkoglu AN, Haas R, Kobbe G (2005b) Comparison of interferon versus thalidomide versus RIC allotransplant for maintenance/ consolidation therapy after autologous stem cell transplantation in patients with multiple myeloma: a single center experience. Blood 106(11):1168
53. Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, Ruf L, Haas R, Kobbe G (2006) Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 34:1296-1302 (Pubitemid 44374839)
54. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet JC (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131-3136 (Pubitemid 28492319)
55. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227-9233
56. Galimberti S, Morabito F, Guerrini F, Palumbo GA, Azzara A, Martino M, Benedetti E, Di Raimondo F, Petrini M (2003) Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 120:405-412 (Pubitemid 36241496)
57. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf I, Gorschluter M (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132:584-593 (Pubitemid 43381591)
58. Goldschmidt H, Hegenbart U, Haas R, Hunstein W (1996) Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 17:691-697 (Pubitemid 26156299)
59. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R (1997) Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 98:736-744 (Pubitemid 27386558)
60. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Engenhart R, Wannenmacher M, Haas R (1998) Peripheral blood progenitor cell transplantation in multiple myeloma following highdose melphalan-based therapy. Recent Results Cancer Res 144:27-35
61. Haas R, Hohaus S, Egerer G, Ehrhardt R, Witt B, Hunstein W (1992) Recombinant human granulocyte- macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. Bone Marrow Transplant 9:459-465
62. Haas R, Gericke G, Witt B, Cayeux S, Hunstein W (1993) Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation. Exp Hematol 21:109-113 (Pubitemid 24216741)
63. Haas R, Moos M, Karcher A, Mohle R, Witt B, Goldschmidt H, Fruhauf S, Flentje M, Wannenmacher M, Hunstein W (1994a) Sequential highdose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 12:1685-1692 (Pubitemid 24245005)
64. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W (1994b) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787-3794 (Pubitemid 24175570)
65. + hematopoietic progenitor cells. Blood 85:1936-1943
66. Haas R, Schmid H, Hahn U, Hohaus S, Goldschmidt H, Murea S, Kaufmann M, Wannenmacher M, Wallwiener D, Bastert G, Hunstein W (1997) Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer. Eur J Cancer 33:372-378
67. Hamamura K, Matsuda H, Takeuchi Y, Habu S, Yagita H, Okumura K (1996) A critical role of VLA-4 in erythropoiesis in vivo. Blood 87:2513-2517 (Pubitemid 26086897)
68. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG, Renaud M, Moreau P, Avet-Loiseau H (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91:1498-1505 (Pubitemid 44736116)
69. Heyll A, Sohngen D, Kobbe G, Schneider P, Bauser U, Thiele KP, Wehmeier A, Sudhoff T, Quenzel EM, Rieth C, Wernet P, Fischer J, Frick M, Aul C (1997) Idarubicin, melphalan and cyclophosphamide: an intensified high-dose regimen for the treatment of myeloma patients. Leukemia 11(Suppl 5): S32-S34 (Pubitemid 28048092)
70. Hohaus S, Goldschmidt H, Ehrhardt R, Haas R (1993) Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol 21:508-514 (Pubitemid 24212343)
71. Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Farber L, Burger KJ, Goldschmidt H, Hoelzer D, Haas R (1998) Recombinant human granulocyte and granulocyte-macrophage colony- stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 22:625-630 (Pubitemid 28486359)
72. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731 (Pubitemid 34111380)
73. Hughes PE, Pfaff M (1998) Integrin affinity modulation. Trends Cell Biol 8:359-364 (Pubitemid 28398427)
74. Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Cowan JM, Anderson KC (2007) Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21:151-157 (Pubitemid 44921846)
75. Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL, Chen H, Schuening FG (2005) Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 35:1165-1169 (Pubitemid 40895172)
76. Johnson RJ, Owen RG, Smith GM, Child JA, Galvin M, Newton LJ, Rawstron A, Major K, Woodhead V, Robinson F, Jack A, Morgan GJ (1996) Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplant 17:723-727 (Pubitemid 26156304)
77. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang BB, Gardner S, Miller-Messana MA, Shoemaker D, Garst J, Schwab G (2000) Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18:2522-2528 (Pubitemid 30432517)
78. Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P, Dumontet C, Moullet I, Eljaafari-Corbin A, Neidhardt-Berard EM, Bouafia F, Coiffier B (1998) High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 91:3148-3155 (Pubitemid 28193863)
79. Khaldoyanidi S, Denzel A, Zoller M (1996) Requirement for CD44 in proliferation and homing of hematopoietic precursor cells. J Leukoc Biol 60:579-592 (Pubitemid 26400414)
80. Khaldoyanidi S, Schnabel D, Fohr N, Zoller M (1997) Functional activity of CD44 isoforms in haemopoiesis of the rat. Br J Haematol 96:31-45
81. Kiel K, Cremer FW, Ehrbrecht E, Wallmeier M, Hegenbart U, Goldschmidt H, Moos M (1998) First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield. Bone Marrow Transplant 21:1109-1115 (Pubitemid 28256652)
82. Kinashi T, Springer TA (1994) Adhesion molecules in hematopoietic cells. Blood Cells 20:25-44 (Pubitemid 24247767)
83. Kobbe G, Hieronimus N, Graef T, Bruns I, Cibere A, Zohren F, Steidl U, Germing U, Haas R, Fenk R (2006) Combined use of palifermin and pegfilgrastim significantly reduces toxicity of highdose therapy and autologous blood stem cell transplantation in patients with multiple myeloma. Session type. Blood 108(11):5260
84. Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB (1995) Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 85:1659-1665
85. Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP III (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 13:183-196 (Pubitemid 46112369)
86. Korthals M, Safaian N, Kronenwett R, Maihofer D, Schott M, Papewalis C, Diaz BE, Winter M, Czibere A, Haas R, Kobbe G, Fenk R (2007) Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med 5:46
87. Kotto-Kome AC, Fox SE, Lu W, Yang BB, Christensen RD, Calhoun DA (2004) Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res 50:55-58 (Pubitemid 38479668)
88. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520
89. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B (2009) Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 101:100-106
90. Ladetto M, Omede P, Sametti S, Donovan JW, Astolfi M, Drandi D, Volpato F, Giaccone L, Giaretta F, Palumbo A, Bruno B, Pileri A, Gribben JG, Boccadoro M (2002) Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. Exp Hematol 30:529-536 (Pubitemid 34626649)
91. Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosinol L, Sureda A, de la Rubia J, Garcia-Larana J, Martinez-Martinez R, Hernandez-Garcia MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernandez-Ruiz B, Garcia-Frade J, Rivas-Gonzalez C, Alegre A, Blade J, San Miguel JF (2008) Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 26:5775-5782
92. Laura R, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Blade J, Montserrat E (2006) Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 76:405-408
93. Leavesley DI, Oliver JM, Swart BW, Berndt MC, Haylock DN, Simmons PJ (1994) Signals from platelet/endothelial cell adhesion molecule enhance the adhesive activity of the very late antigen-4 integrin of human CD34+ hemopoietic progenitor cells. J Immunol 153:4673-4683 (Pubitemid 24346863)
94. + cells comparing continuous intravenous vs subcutaneous administration of rhG-CSF in normal donors. Bone Marrow Transplant 36:1027-1031
95. Lemoli RM, Cavo M, Fortuna A (1996) Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma. J Hematother 5:339-349
96. + B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. Br J Haematol 107:419-428
97. + cells to support single or tandem high-dose chemotherapy. Blood 95:2234-2239
98. + haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. Br J Haematol 110:71-81
99. Liesveld JL, Winslow JM, Frediani KE, Ryan DH, Abboud CN (1993) Expression of integrins and examination of their adhesive function in normal and leukemic hematopoietic cells. Blood 81:112-121 (Pubitemid 23013684)
100. Lilienfeld-Toal M, Hahn-Ast C, Bertolini F, Bila J, Boulin M, Oakervee H, Cibeira T, Cook G, Fenk R, Waage A, Glasmacher A (2007) Longer duration of thalidomide monotherapy results in improved outcome in relapsed/refractory multiple myeloma. Blood [abstract] 110:2725
101. Lincz LF, Crooks RL, Way SL, Granter N, Spencer A (2001) Tumour kinetics in multiple myeloma before, during, and after treatment. Leuk Lymphoma 40:373-384 (Pubitemid 32401394)
102. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, Van Der HB, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H (2008) Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 93(1):124-127 (Pubitemid 351156161)
103. Lopez-Perez R, Garcia-Sanz R, Gonzalez D, Balanzategui A, Chillon MC, Alaejos I, Mateos MV, Caballero MD, Mateo G, Nieto MJ, Gonzalez M, San Miguel JF (2000) The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Leukemia 14:1493-1499 (Pubitemid 30599331)
104. Lopez-Perez R, Garcia-Sanz R, Gonzalez D, Balanzategui A, Chillon MC, Alaejos I, Mateos MV, Caballero MD, Corral M, Orfao A, Gonzalez M, San Miguel JF (2001) Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 28:665-672 (Pubitemid 33014600)
105. Maas RE (2008) A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep 16:257-259
106. Macintyre W (1850) Case of mollities and fragilitas ossium accompanied with urine strongly charged with animal matter. Med Chir Trans Lond 33:211-232
107. Macro M, Divine M, Jaccard A, Bouscary D, Leblond V, Janvier M, Genet P, Castaigne S, Royer B, Allard C, Chevret S, Fermand J-P (2006) Dexamethasone + thalidomide compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial. Blood [abstract] 108:57
108. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, Bandini G, Motta MR, Testoni N, Amabile M, Ottaviani E, Vianelli N, De Vivo A, Gozzetti A, Tura S, Cavo M (2000) Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 18:2273-2281 (Pubitemid 30350220)
109. Martinelli G, Agazzi A, Laszlo D, Santoro P, Mancuso P, Pruneri GC, Greco P, Bertolini F (2003) Idarubicin containing regimen in multiple myeloma: preliminary results of a pilot study using a modified "TANDEM" transplant program. Leuk Lymphoma 44:299-302
110. Martin-Murea S, Voso MT, Hohaus S, Pforsich M, Fruehauf S, Goldschmidt H, Hegenbart U, Haas R (1998) The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery. Br J Haematol 101:582-585 (Pubitemid 28266956)
111. McElwain T, Powles RL (1983) High-dose intravenous melphalan for plasma cell leukemia and myeloma. Lancet 2:822-824 (Pubitemid 13013370)
112. Mitterer M, Lanthaler AJ, Schnabel B, Svaldi M, Oduncu F, Coser P, Emmerich B, Huemer H, Straka C (2001) Peripheral blood monoclonal B-cells predict the event free survival in multiple myeloma. Leuk Lymphoma 41:387-395 (Pubitemid 32499422)
113. Miyake K, Medina KL, Hayashi S, Ono S, Hamaoka T, Kincade PW (1990) Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in longterm bone marrow cultures. J Exp Med 171:477-488 (Pubitemid 20059042)
114. Miyake K, Weissman IL, Greenberger JS, Kincade PW (1991) Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J Exp Med 173:599-607
115. + cells with a different antigenic profile compared with use during steady-state hematopoiesis. Bone Marrow Transplant 14:827-832
116. + progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. Exp Hematol 23:1535-1542
117. Mohle R, Moore MA, Nachman RL, Rafii S (1997) Transendothelial migration of CD34+ and mature hematopoietic cells: an in vitro study using a human bone marrow endothelial cell line. Blood 89:72-80 (Pubitemid 26428180)
118. + hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 91:4523-4530
119. 2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99:731-735
120. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197-223 (Pubitemid 32368034)
121. Myeloma Trialists' Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832-3842
122. Myeloma Trialists' Collaborative Group (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113:1020-1034
123. Nestle FO, Farkas A, Conrad C (2005) Dendritic-cell- based therapeutic vaccination against cancer. Curr Opin Immunol 17:163-169 (Pubitemid 40343103)
124. Ocio EM, Mateos MV, Maiso P, Pandiella A, San- Miguel JF (2008) New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 9:1157-1165
125. Olivieri A, Scortechini I, Capelli D, Montanari M, Lucesole M, Gini G, Troiani M, Offidani M, Poloni A, Masia MC, Raggetti GM, Leoni P (2004) Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. Bone Marrow Transplant 34:693-702 (Pubitemid 39406053)
126. Oostendorp RA, Spitzer E, Brandl M, Eaves CJ, Dormer P (1998) Evidence for differences in the mechanisms by which antibodies against CD44 promote adhesion of erythroid and granulopoietic progenitors to marrow stromal cells. Br J Haematol 101:436-445 (Pubitemid 28266934)
127. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Dammacco F, Ciccone G, Boccadoro M (2004) Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104:3052-3057 (Pubitemid 39507119)
128. + immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplant 23:1245-1250
129. Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van Rhee F, Zangari M, Walker R, Hollmig K, Shaughnessy JD Jr, Epstein J, Krishna S, Crowley J, Barlogie B (2007) Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 136:393-399 (Pubitemid 46046297)
130. Prosper F, Stroncek D, McCarthy JB, Verfaillie CM (1998) Mobilization and homing of peripheral blood progenitors is related to reversible down-regulation of alpha4 beta1 integrin expression and function. J Clin Invest 101:2456-2467 (Pubitemid 28270440)
131. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436 (Pubitemid 46630462)
132. Reiffers J, Faberes C, Boiron JM, Marit G, Foures C, Ferrer AM, Cony-Makhoul P, Puntous M, Bernard P, Vezon G (1994) Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother 3:185-191
133. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben Yehuda D, Lonial S, Goldschmidt H, Reece D, San Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498
134. Roberts AW, DeLuca E, Begley CG, Basser R, Grigg AP, Metcalf D (1995) Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy. Stem Cells 13:512-516
135. Rosel M, Khaldoyanidi S, Zawadzki V, Zoller M (1999) Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation. Exp Hematol 27:698-711 (Pubitemid 29181446)
136. Roussel M, Huynh A, Moreau P, Harousseau JL, Hulin C, Caillot D, Fruchart C, Marit G, Pegourie B, Attal M (2008) Bortezomib (BOR) and high dose melphalan (HDM) as conditioning regimen before autologous stem cell transplantation (ASCT) for de novo multiple myeloma (MM): final results of the IFM phase II study VEL/MEL. ASH Annual Meeting Abstracts 112:160
137. + peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86:390-397
138. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H, Hunter A, Russell NH (1995) Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85:1666-1672
139. Schofield R (1983) The stem cell system. Biomed Pharmacother 37(8):375-380
140. Shaughnessy JD Jr., Qu P, Edmondson R, Herman D, Zhou Y, Tian E, van Rhee F, Pineda-Roman M, Alsayed Y, Anaissie E, Qiang YW, Epstein J, Yaccoby S, Williams D, Zhan F, Stephens O, Hoering A, Crowley J, Barlogie B (2008) Changes in the expression of proteasome genes in tumor cells following short-term proteasome inhibitor therapy predicts survival in multiple myeloma treated with bortezomib-containing multi-agent chemotherapy. ASH Annual Meeting Abstracts 112:733
141. Simmons PJ, Masinovsky B, Longenecker BM, Berenson R, Torok-Storb B, Gallatin WM (1992) Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood 80:388-395
142. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD (1988) Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1:1194-1198
143. Soligo D, Schiro R, Luksch R, Manara G, Quirici N, Parravicini C, Lambertenghi DG (1990) Expression of integrins in human bone marrow. Br J Haematol 76:323-332 (Pubitemid 20367840)
144. Solly S (1844) Remarks on the pathology of mollities ossium with cases. Med Chir Trans Lond 27:435-461
145. Spencer A, Prince M, Roberts AW, Bradstok K, Prosser I (2006) First analysis of the Australian leukemia and lymphoma group trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation for patients with multiple myeloma. Blood [abstract] 108:58
146. Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P (2005) Fixed-dose single administration of pegfilgrastim vs daily filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 35:889-893 (Pubitemid 40667631)
147. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, Graf T, Rohr UP, Bork S, Kronenwett R, Haas R, Kobbe G (2005) Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 35:33-36 (Pubitemid 40090053)
148. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, White M, DiPersio J, Anderson KC, Berenson J (2001) Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 19:3771-3779 (Pubitemid 32844791)
149. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ (2001) Minimal residual disease in leukaemia patients. Lancet Oncol 2:409-417 (Pubitemid 33585945)
150. Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Pequignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Metivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L (2006) A novel dendritic cell subset involved in tumor immunosurveillance 1. Nat Med 12:214-219 (Pubitemid 43214748)
151. Tarella C, Benedetti G, Caracciolo D, Castellino C, Cherasco C, Bondesan P, Omede P, Ruggieri D, Gianni AM, Pileri A (1995) Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. Br J Haematol 91:535-543
152. Teixido J, Hemler ME, Greenberger JS, Anklesaria P (1992) Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma. J Clin Invest 90:358-367
153. Thunberg U, Banghagen M, Bengtsson M, Christensen LD, Geisler CH, Gimsing P, Lenhoff S, Mortensen BT, Olofsson T, Simonsson B, Andersen NS, Sundstrom C, Swedin A, Sallstrom JF, Thuresson B, Westin J, Carlson K (1999) Linear reduction of clonal cells in stem cell enriched grafts in transplanted multiple myeloma. Br J Haematol 104:546-552 (Pubitemid 29119280)
154. + cells. Blood 84:2930-2939
155. Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, Fassas A, Tindle S, Nelson J, Juttner C, Tsukamoto A, Hallagan J, Atkinson K, Reading C, Hoffman R, Barlogie B (1998) Collection, tumor contamination, and engraftment kinetics of highly purified hemato poietic progenitor cells to support high dose therapy in multiple myeloma. Blood 91:4489-4495 (Pubitemid 28270295)
156. Valteau-Couanet D, Faucher C, Auperin A, Michon J, Milpied N, Boiron JM, Bourhis JH, Gisselbrecht C, Vernant JP, Pinna A, Bendahmane B, Delabarre F, Benhamou E (2005) Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplant 36:547-552 (Pubitemid 43118150)
157. van Rhee F (2007) Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system. Clin Cancer Res 13:1353-1355
158. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD Jr, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B (2007) High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 110(3):827-832 (Pubitemid 47267417)
159. Vanstraelen G, Frere P, Ngirabacu MC, Willems E, Fillet G, Beguin Y (2006) Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 34:382-388
160. Verfaillie CM, McCarthy JB, McGlave PB (1991) Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin. J Exp Med 174:693-703
161. Verfaillie C, Hurley R, Bhatia R, McCarthy JB (1994) Role of bone marrow matrix in normal and abnormal hematopoiesis. Crit Rev Oncol Hematol 16:201-224 (Pubitemid 24210173)
162. Vescio RA, Han EJ, Schiller GJ, Lee JC, Wu CH, Cao J, Shin J, Kim A, Lichtenstein AK, Berenson JR (1996) Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 18:103-110 (Pubitemid 26289641)
163. Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, DiPersio J, Anderson K, Berenson J (1999) Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 93:1858-1868 (Pubitemid 29128487)
164. Viardot A, Kronenwett R, Deichmann M, Haas R (1998) The human immunodeficiency virus (HIV)-type 1 coreceptor CXCR-4 (fusin) is preferentially expressed on the more immature CD34+ hematopoietic stem cells. Ann Hematol 77:193-197 (Pubitemid 28550027)
165. Voena C, Locatelli G, Castellino C, Omede P, Ladetto M, Zappone E, Milani R, Perfetti V, Boccadoro M, Pileri A, Lusso P, Villa C, Malnati M, Corradini P (2002) Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. Br J Haematol 117:642-645 (Pubitemid 34539241)
166. + cells across uncoated or fibronectin-coated filters. Exp Hematol 27:1806-1814
167. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961-3969
168. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142 (Pubitemid 350146108)
169. Whetton AD, Graham GJ (1999) Homing and mobilization in the stem cell niche. Trends Cell Biol 9:233-238 (Pubitemid 29244135)
170. Winter JN, Lazarus HM, Rademaker A, Villa M, Mangan C, Tallman M, Jahnke L, Gordon L, Newman S, Byrd K, Cooper BW, Horvath N, Crum E, Stadtmauer EA, Conklin E, Bauman A, Martin J, Goolsby C, Gerson SL, Bender J, O'Gorman M (1996) Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte- macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 14:277-286 (Pubitemid 26020024)
171. Yamaguchi M, Ikebuchi K, Hirayama F, Sato N, Mogi Y, Ohkawara J, Yoshikawa Y, Sawada K, Koike T, Sekiguchi S (1998) Different adhesive characteristics and VLA-4 expression of CD34(+) progenitors in G0/G1 versus S + G2/M phases of the cell cycle. Blood 92:842-848 (Pubitemid 28355467)
172. Yanai N, Sekine C, Yagita H, Obinata M (1994) Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis. Blood 83:2844-2850 (Pubitemid 24142715)
173. Zamboni WC (2003) Pharmacokinetics of pegfilgrastim. Pharmacotherapy 23:9S-14S
174. Zhou P, Zhang Y, Martinez C, Kalakonda N, Nimer SD, Comenzo RL (2003) Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. Blood 102:477-479 (Pubitemid 36841963)